Steven Ringel

Steven Ringel is the Founder and CEO of Nome Therapeutics, the Operating System for Personalized Therapeutics, turning every rare disease patient's genome into an actionable treatment plan and helping execute on it at the lowest cost and highest speed in the industry. He also founded the Kizuna Foundation, a nonprofit developing gene replacement therapy for KIZ-mutated retinitis pigmentosa, inspired by his own family's experience with a rare retinal condition. Before Nome, Steven held leadership roles at Illumina, Sema4, Tempus, and GeneDx, spanning the arc of genomic medicine's commercialization. He serves on the board of the Foundation Fighting Blindness. Steven is based in La Jolla, California.